Responses
Regular and young investigator award abstracts
Clinical trials in progress
372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager
Compose a Response to This Article
Other responses
No responses have been published for this article.
